Tevogen Bio Holdings Inc (TVGN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Tevogen Bio Holdings Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Tevogen Bio Holdings Inc's ROI in the second quarter of 2026?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Tevogen Bio Holdings Inc 's return on investment (ROI) in its second quarter of 2026
Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a prominent clinical-stage biotech company specializing in immunotherapy, has recently reported its financial results for the third quarter of 2024, ending September 30. This announcement marks a pivotal moment for Tevogen as it highlights significant advancements in its financial standing and pivotal strategic initiatives aimed at amplifying its immunotherapy developments. Key Financial HighlightsTevogen Bio showcased a remarkable return on average invested assets (ROI) of 51.99% for the second quarter of 2024, a figure notably higher than the average ROI of 12.13% within the company’s historical data. However, an analysis of the latest reports shows a decrease in ROI compared to the March 31, 2024 quarter, primarily due to a decline in net income. This decrease in ROI is accompanied by a change in the company s overall ranking within the Healthcare sector, sliding from 60th to 64th among peers, as 11 other companies reported higher ROI statistics.
Tevogen Bio: Navigating Tax Obligations and Embracing AI for Future GrowthIn a press release dated October 21, 2024, Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotechnology company based in Warren, New Jersey, clarified the recent decision by its Chief Scientific Officer (CSO), Dr. Neal Flomenberg, to sell shares. According to Chief Financial Officer Kirti Desai, the sale was necessary solely to meet tax obligations arising from the vesting of restricted stock units (RSUs). This incident has raised interest among stakeholders, especially given the context of Tevogen s rising share prices and overall performance metrics.In the five trading days leading up to the announcement, Tevogen Bio Holdings Inc. shares soared by a remarkable 69.44%. This surge was notable given the company s reported return on average invested assets (ROI) of 51.99% in the second quarter of 2024—well above the average ROI for the company of 12.13%. However, it is crucial to mention that this ROI reflects a slight decline from the previous quarter ending March 31, 2024, attributed to a decrease in net income. This reduction in net income subsequently impacted the overall ranking within the Healthcare sector, where Tevogen fell from 58 to 59 based on its return on investment relative to its peers.
In an era dominated by rapid technological advancements, the intersection of biotechnology and artificial intelligence is reshaping the landscape of healthcare. Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a clinical-stage specialty immunotherapy company based in Warren, New Jersey, is rising to prominence in this transformative arena. With a commitment to developing off-the-shelf, genetically unmodified T cell therapeutics for a range of medical challenges—including infectious diseases and cancers—Tevogen is not only pushing the boundaries of immunotherapy but also fostering an unprecedented wave of public support. Unprecedented Public SupportTevogen s CEO recently expressed heartfelt gratitude for the overwhelming support the company has received from the public regarding its innovative business model. The enthusiasm surrounding Tevogen stems from its commitment to patient accessibility, a principle that underpins its strategy for commercial success. As the CEO reaffirmed his dedication to updating stakeholders with further insights into the company s trajectory, it is crystal clear that Tevogen is positioning itself as a pioneering force in the biotech landscape.
In an era marked by unprecedented advancements in biotechnology, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) stands out as a clinical-stage specialty immunotherapy company focused on treating infectious diseases and cancers. Recent developments, including ambitious revenue projections and a noteworthy return on investment, have prompted the company’s leadership to reaffirm their commitment to transparency regarding its multi-billion-dollar assets. The Current Landscape:Tevogen Bio recently made news with the announcement of a potential revenue generation exceeding $1 billion, a significant milestone that underscores the market s confidence in its innovative approach. The company achieved a remarkable return on average invested assets (ROI) of 51.99% in its second quarter of 2024, dwarfing the industry average ROI of 12.13%. This performance indicates not only efficient use of capital but also promises substantial growth potential for the future.Expanding the Therapeutic Pipeline:The company is actively expanding its therapeutic pipeline to address various medical challenges. Notably, Tevogen s commitment to oncology solutions complements its focus on Long COVID therapies. The company’s ExacTcell technology platform, which utilizes off-the-shelf, genetically unmodified T cell therapeutics, aims to deliver effective treatments without the complex challenges associated with genetically modified therapies. This innovative approach aligns with the growing demand for safer and more accessible cancer treatment options, showcasing Tevogen’s responsiveness to an urgent market need.
Tevogen Bios Innovation Amplifies with Prof. Sten Vermund s Appointment as Dean of the USF Health College of Public Health In a groundbreaking announcement, Tevogen Bio Holdings Inc acknowledges and congratulates Professor Sten Vermund, MD, PhD, for his recent appointment as the esteemed dean of the University of South Florida (USF) Health College of Public Health. This remarkable milestone not only propels Professor Vermund s distinguished career but also marks a new era of innovation and advancement for Tevogen Bio and the broader field of public health. Professor Vermund s extensive expertise and contributions to the medical and public health realms have garnered him immense recognition and respect in the industry. As the Chairperson of Tevogen Bios Innovation and Public Health Advisory Board, his visionary leadership has spearheaded the development of groundbreaking solutions aimed at improving global health outcomes. This recent appointment as the dean of USF Health College of Public Health further solidifies his influential role in shaping the future of healthcare.
Tevogen Bio: A Trailblazer in Immunotherapy Biotech Highlights Achievements, Growth Plans, and Share Buyback Consideration WARREN, N.J., July 11, 2024 - Tevogen Bio Holding Inc. (Tevogen or Tevogen Bio) (Nasdaq: TVGN), a pioneering clinical-stage specialty immunotherapy biotech company focusing on the development of off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has recently released a letter to its esteemed stockholders. This letter sheds light on the remarkable accomplishments, future growth strategies, and the potential consideration of a share buyback, underscoring Tevogen Bio s commitment to maximizing shareholder value and further enhancing its position in the fast-paced biotech industry. In a period marked by groundbreaking advancements, Tevogen Bio has consistently pushed the boundaries of immunotherapy treatments. Through rigorous research and development, the company has revolutionized the field by introducing innovative and genetically unmodified T cell therapies. These groundbreaking therapies hold immense promise in treating various complex diseases, including cancer, neurological disorders, and viral infections. Tevogen Bio s dedication to advancing patient care has positioned it as a leading industry player, garnering widespread recognition and investor confidence.
Warren, N.J., July 08, 2024 - Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (Tevogen) (Nasdaq: TVGN), extends his heartfelt congratulations to Salesforce CEO Marc Benioff on the prestigious recognition of receiving the Yale Legend in Leadership Award. This distinguished accolade, presented at the bi-annual CEO Summit held by Yale School of Management, celebrates exceptional individuals who exemplify the symbiotic relationship between business success and social prosperity. The Yale Legend in Leadership Award, created 35 years ago, aims to honor current and former CEOs who serve as living legends, inspiring chief executives across industries, sectors, and nations. Marc Benioff s remarkable achievements in driving corporate success while championing social responsibility have undoubtedly earned him this esteemed recognition.
Financial Statements
Tevogen Bio Holdings Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
